«Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia». The Lancet, 02-02-2021. DOI: 10.1016/s0140-6736(21)00234-8.
«Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia». Lancet, 396, 10255, 9-2020, pàg. 887–897. DOI: 10.1016/S0140-6736(20)31866-3. PMC: 7471804. PMID: 32896291.
Logunov, Denis Y; Dolzhikova, Inna V; others «Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia». The Lancet, 396, 10255, 2020, pàg. 887–97. DOI: 10.1016/s0140-6736(20)31866-3. ISSN: 0140-6736. PMC: 7471804. PMID: 32896291.
«Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia». Lancet, 396, 10255, 9-2020, pàg. 887–897. DOI: 10.1016/S0140-6736(20)31866-3. PMC: 7471804. PMID: 32896291.
Logunov, Denis Y; Dolzhikova, Inna V; others «Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia». The Lancet, 396, 10255, 2020, pàg. 887–97. DOI: 10.1016/s0140-6736(20)31866-3. ISSN: 0140-6736. PMC: 7471804. PMID: 32896291.